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Available online 8 January 2016AbstractPurpose: To compare the effect of Homatropine and Diclofenac eye drops for reducing pain after photorefractive keratectomy (PRK).
Methods: This randomized, double-masked, interventional study included 32 patients (64 eyes) who underwent bilateral PRK. After operation,
patients received Homatropine eye drops in one eye and Diclofenac eye drops in the fellow eye for 48 h. The level of pain was evaluated using
visual analogue scale (VAS), verbal rating scale (VRS), and pain rating index (PRI) at 0.5, 24, and 48 h after operation.
Results: The level of pain was statistically similar between the two eyes half an hour after operation; however, Diclofenac eyes had significantly
less pain 24 h after operation (1.7 ± 1.4 vs 5.8 ± 2.1, P < 0.001 for VAS, 0.6 ± 0.6 vs 2.4 ± 1.1, P < 0.001 for VRS, and 3.4 ± 3.4 vs 12.0 ± 6.9,
P < 0.001 for PRI, respectively). Also, 48 h after surgery, the pain scores were less in the Diclofenac eyes (1.6 ± 1.8 vs 3.4 ± 2.8, P < 0.001 for
VAS, 0.6 ± 0.6 vs 1.2 ± 0.9, P < 0.001 for VRS, and 3.3 ± 3.7 vs 6.5 ± 6.2, P < 0.001 for PRI). No case with delayed epithelial healing in both
groups was observed.
Conclusion: The effect of Homatropine seems to be lower compared to Diclofenac for reducing pain after photorefractive keratectomy.
Copyright © 2015, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Photorefractive keratectomy (PRK) is a safe and effective
procedure for correction of mild to moderate refractive error.
One of the main drawbacks of this operation is significant
postoperative pain secondary to removal of epithelium and
exposure of the nerve endings.1 Pain is especially severe in the
first 24 h after surgery, and despite using therapeutic contact
lens, the discomfort may be intolerable.1 Several medications
with different success rates and complications have been* Corresponding author. Rassoul Akram Hospital, Iran University of Medical
Sciences, Tehran, Iran.
E-mail address: Aghaee.h1376@yahoo.com (H. Aghaei).
Peer review under responsibility of the Iranian Society of Ophthalmology.
http://dx.doi.org/10.1016/j.joco.2015.11.006
2452-2325/Copyright © 2015, Iranian Society of Ophthalmology. Production and ho
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).reported to be useful for reducing post-PRK pain. These
include systemic analgesics and topical nepafenac, Diclofe-
nac, tetracaine, ketorolac, proparacaine, and morphine.2e9
Cycloplegics are medications that are usually used for
inducing mydriasis as well as pain relief in ophthalmology.
The long ciliary nerves are given off from the nasociliary
nerve which is a branch of the ophthalmic division of tri-
geminal nerve.10 Acetylcholine is a common neurotransmitter
in this pathway which affects muscarinic receptors in iris-
ciliary body.11 Considering the effect of cycloplegics on
aborting ciliary body spasm, they are widely used to smooth
the pain secondary to ocular surface abrasions and uveitis.12,13
In a recent study, we assessed the effect of a topical cyclo-
plegic drug, Homatropine, after PRK.14 The pain was
significantly less in Homatropine-used eyes compared withsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
Table 1
Means ± standard deviations of pain scores on visual analogue scale (VAS),
verbal rating scale (VRS), and pain rating index (PRI) at different time points
after photorefractive keratectomy.
Homatropine group Diclofenac group P value
VAS at 0.5 h 2.2 ± 2.3 2.4 ± 2.6 0.37
VAS at 24 h 1.7 ± 1.4 5.8 ± 2.1 <0.001
VAS at 48 h 1.6 ± 1.8 3.4 ± 2.8 <0.001
VRS at 0.5 h 0.8 ± 0.8 0.9 ± 0.9 0.26
VRS at 24 h 0.6 ± 0.6 2.4 ± 1.1 <0.001
VRS at 48 h 0.6 ± 0.6 1.2 ± 0.9 <0.001
PRI at 0.5 h 3.5 ± 3.1 3.8 ± 3.7 0.64
PRI at 24 h 3.4 ± 3.4 12.0 ± 6.9 <0.001
PRI at 48 h 3.3 ± 3.7 6.5 ± 6.2 <0.001
88 K. Abri Aghdam et al. / Journal of Current Ophthalmology 27 (2015) 87e91control fellow eyes. Postoperative medications for control
fellow eyes were topical Betamethasone, four times daily,
topical Chloramphenicol, four times daily, and oral Acet-
aminophen, as needed by patient's discretion. In the present
study, the effect of topical Homatropine on relieving pain
after PRK was compared with a topical nonsteroidal anti-
inflammatory drop, Diclofenac, which has been approved
by the FDA for reducing pain after refractive surface
ablation.
Methods
In this double-masked contralateral clinical trial, 32 pa-
tients (64 eyes) who were candidates for bilateral PRK
surgery between January and April 2011 were included.
The study was conducted in accordance with the ethical
standards stated in the 1964 Declaration of Helsinki and
approved by the Eye Research Center Ethics Committee
with informed consent obtained from patients. All patients
underwent initial complete ocular examinations including
manifest and cycloplegic refraction, slit-lamp examination,
intraocular pressure measurement, and dilated fundus ex-
aminations. Patients with hyperopia, anisometropia, previous
ocular surgeries, and history of neurosensory pain disorders
were excluded.
Epithelium was removed by 20% alcohol over the cornea
for 20 s in an 8.5e9 mm ring and using golf headed spatula.
Laser ablation was performed using a Technolas 217 instru-
ment (Bausch & Lomb).
After corneal ablation, sterile surgical sponge soaked in
Mitomycin C was placed over the cornea, and then the cornea
surface was washed with 100 ml of balanced salt solution.
After surgery, a plano bandage contact lens was placed on the
cornea, and the contact lenses were removed at the third
postoperative day. Postoperative medications were topical
betamethasone, four times daily, topical ciprofloxacin, four
times daily, and oral acetaminophen, as needed by patient's
discretion. Topical Homatropine (Sina Darou, Tehran, Iran),
four times daily, was added to the postoperative medications
for one eye (Homatropine eye). For the fellow eye, topical
Diclofenac eye drop (Sina Darou, Tehran, Iran), 4 times
daily, was prescribed. The envelope of the Homatropine and
Diclofenac bottles were removed by one of the authors (KA)
and replaced by a sign indicating the type of the drop which
was known only for the same researcher. The patients were
instructed to use the drops for the same scheduled eye,
and those who reported mistakes were excluded from the
study. All patients were evaluated daily for epithelial wound
healing. Randomization of the eyes was performed by one of
the authors (KA). The surgeon, patients, and researcher
evaluating patients' pain were all unaware of the randomi-
zation process and the eye which was receiving Homatropine
drops.
All the procedures and medications were similar for both
eyes except for Homatropine and Diclofenac eye drops. Before
surgery, patients were oriented to a pain questionnaire by one
of the authors. Pain rating scales were explained to the patientsand reevaluated to confirm their understanding. Patients were
asked about pain and discomfort in each eye and requested to
express their pain experience with three different subjective
pain scoring questionnaires: visual analogue scale (VAS),
verbal rating scale (VRS), and Mac-Gill pain questionnaire.
For visual analogue scale, the patients were asked to indicate
their pain sensation severity in a linear line marked from 0 for
“no pain” to 10 for “the most severe intolerable pain I have
ever experienced.”15 For recording verbal rating scale (VRS),
patients were asked to rate their experience of pain on the
Keele's verbal pain chart.16,17 This scale allowed them to score
pain in a semiquantitative way: 0 ¼ no pain, 1 ¼ minimal pain,
2 ¼ moderate pain, 3 ¼ severe pain, and 4 ¼ agonizing pain.
McGill Pain Questionnaire measures pain score as a sum of
the sensory and affective pain rating index (S-PRI and A-
PRI).18,19
Data were entered using SPSS software (SPSS 15.0, SPSS
Inc., Chicago, IL). KolmogoroveSmirnov and QeQ plots
were used for testing the distribution of variables and Wil-
coxon signed rank test was used for analysis. P value less than
0.05 was considered significant.
Results
Thirty-three patients entered in this study. One patient was
excluded due to using the drops for both eyes; therefore, the
data from 32 patients were analyzed. Mean corrected refrac-
tive error was not different between Homatropine and Diclo-
fenac groups (3.3 ± 1.3 and 3.4 ± 1.4, respectively,
P ¼ 0.4).
Table 1 shows the pain scores of the patients. Since the
KolmogoroveSmirnov test showed a non-normal distribution
of some variables, we repeated the analysis using a nonpara-
metric test (Wilcoxon signed rank test). VAS, VRS, and PRI
scores, 0.5 h after operation, was not significantly different
between Homatropine and control eyes (P ¼ 0.3, P ¼ 0.2, and
P ¼ 0.6, respectively). Figs. 1e3 represent overlay scatterplots
showing pain scores in terms of VAS, VRS, and PRI,
respectively. Twenty-four and 48 h after surgery, pain scores
on VAS, VRS, and PRI were all significantly lower in Diclo-
fenac eyes. The contact lenses were removed at the third
Fig. 1. Overlay scatterplot showing pain scores in terms of visual analogue scale (VAS) in Homatropine group versus Diclofenac group.
Fig. 2. Overlay scatterplot showing pain scores in terms of verbal rating scale (VRS) in Homatropine group versus Diclofenac group.
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Fig. 3. Overlay scatterplot showing pain scores in terms of pain rating index (PRI) in Homatropine group versus Diclofenac group.
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4th day after surgery in all eyes.
Discussion
Postoperative pain is one of the most significant disad-
vantages of PRK.20e23 Exposure of traumatized nerve
endings causes severe postoperative pain which usually
lasts for the first 3e4 days until corneal surface re-
epithelialization occurs. There is not a general agreement
on the best approach to manage postoperative pain in these
patients. A variety of systemic and topical medications have
been used for pain reduction after PRK. Oral nonsteroidal
anti-inflammatory drugs (NSAIDs), Gabapentin, and opiates
are among oral medications being used with different suc-
cess and complication rates.22e24 Topical NSAID drugs are
among the most popular medications to control post-PRK
pain. Diclofenac and Ketorolac have been approved by the
FDA for pain control after surface ablations. Bromfenac, a
recently approved topical NSAID for the treatment of post
cataract surgery inflammation and pain, has been found to
be effective in controlling pain following PRK.3 The pain-
relieving effects, re-epithelialization, and complications
may vary between topical NSAIDs.25 Corneal melting has
been reported after topical NSAID therapy, especially with
Diclofenac drops.26,27 This issue usually occurs in cases
treated without corticosteroid eye drops. No case of delayedepithelial healing or corneal melting was observed in our
series.
The cycloplegics, by relieving ciliary spasm, have a well-
established effect on decreasing pain and discomfort in
corneal lesions.12,13,28 Although our pilot study showed less
pain and discomfort with Homatropine, results of the current
study showed that Diclofenac is significantly superior to
Homatropine for reducing pain after PRK.
Visual analogue score, verbal pain rating scale, and
McGill pain rating index were used to evaluate subjective
pain experience. Although VAS and PRI have been used
frequently in studies to evaluate pain discomfort severity,
Keele's verbal rating scale for pain has scarcely been used,
and this enhances the quality of measurements.16,17 In our
study, each eye was compared with the fellow eye. Eval-
uation of the pain severity in either eye might be influ-
enced by the pain experience in the other eye. Therefore,
the pain scores in this study might be different if Homa-
tropine and Diclofenac eyes were selected from different
individuals.
In conclusion, this study showed that Diclofenac is more
effective than Homatropine for reducing post-PRK pain and
discomfort. Although cycloplegics are cheap and safe without
known deleterious effects on wound healing, their pain-
relieving effects should be studied further. Other cycloplegic
drugs with different cycloplegic durations might be more
effective and convenient to use.
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